Daniel Reich

Daniel Reich is senior investigator at the National Institutes of Health / National Institute of Neurological Disorders and Stroke (NIH/NINDS), where he is chief of the Translational Neuroradiology Section and leads clinical studies focusing mainly on multiple sclerosis (MS). He is also an attending neuroradiologist at the NIH Clinical Center and an adjunct professor of radiology, neurology and biostatistics at Johns Hopkins University.

Daniel’s lab is focused on developing advanced MRI techniques to understand MS and adapting those techniques for clinical trials and patient care by harnessing noninvasive imaging modalities to dissect biological mechanisms of tissue damage. He has authored more than 240 peer-reviewed publications, presented more than 150 invited lectures across the world and has been principal or associate investigator of more than 50 clinical protocols.

Daniel is a founder of the North American Imaging in MS (NAIMS) Cooperative. He currently serves on the board of directors of the Americas Committee for Treatment and Research in MS and the International Advisory Committee on Clinical Trials in Multiple Sclerosis; the board of professors of the Tuscan Ph.D. program in neurosciences at the Universities of Florence, Pisa and Siena; the scientific advisory board of the Canadian Progressive Multiple Sclerosis Cohort; and the editorial board of Multiple Sclerosis Journal. He is also a federal liaison to the International Biomedical Research Alliance.

Daniel is an elected member of the American Society of Clinical Investigation, the 2015 winner of the American Neurological Association’s Derek Denny-Brown Young Neurological Scholar Award, the 2016 winner of the National MS Society’s Barancik Award for Innovation in MS Research and a 2017 winner of the NIH Graduate Partnership Programs Outstanding Mentor Award.

Daniel holds an M.D. from Cornell and a Ph.D. in neurophysiology from The Rockefeller University, where he studied how nerve cells in the visual system encode what we see. He completed a fellowship in diagnostic neuroradiology and residencies in radiology and neurology at Johns Hopkins Hospital.

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Abata Therapeutics

1 followers

Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.


Industries

Employees

11-50

Links